Given Imaging (GIVN) Announces the Degree of Impact the PillCam SB has on GI Patients, Crohn's Disease
More News related to GIVN
- Given Imaging to Host Fourth Quarter 2009 Financial Results Conference Calls
- Given Imaging to Present at the 28th Annual J.P. Morgan Healthcare Conference
- Given Imaging (GIVN) Announces the Degree of Impact the PillCam SB has on GI Patients, Crohn's Disease
- Given Imaging (GIVN) Announces Viability of PillCam Capsule in Pediatric Patients
- Given Imaging (GIVN) Announces PillCam Safe in Children Under 8 Years Old
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Given Imaging Ltd. (NASDAQ: GIVN), the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced that three new studies demonstrate that PillCam SB endoscopy has a clear impact on how physicians manage GI patients, including those patients suspected of having Crohn's disease. The studies were presented at the Gastro 2009 conference taking place in London from November 21 to 25. Given Imaging is exhibiting at booth #83 at the conference.
A 950-patient, single-center study (P2106) analyzing the largest series of capsule endoscopy cases from the UK, led by Dr. Mark E. McAlindon, Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK, examined capsule endoscopy's diagnostic yield and impact on patient management. Results of the study showed that using PillCam SB changed how physicians treated 27 percent of all patients and 79 percent of patients who were subsequently diagnosed with Crohn's disease.
In a poster presentation (P2105), Jorge Cotter, Alto Avenue Hospital Center, in Guimares, Portugal, concluded that physicians can diagnose and classify Crohn's disease earlier by using PillCam SB. The study also found that based upon capsule endoscopy findings, physicians changed their therapeutic strategy for 22 percent of their patients.
Finally, data from a poster (P1471) presented by Paul Thomas, Consultant Gastroenterologist, Musgrove Park Hospital in Somerset, UK, showed that by using PillCam SB, physicians at community hospitals were able to definitively determine the source of GI bleeding in 58 percent of patients who presented with obscure gastrointestinal bleeding (OGIB) and subsequently treated more than one-third of those examined. These results mirror results seen in large, tertiary referral centers. Thomas and colleagues concluded that a normal capsule endoscopy indicates a good prognostic course.
Related Categories
Corporate NewsStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
